Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Immunome (IMNM) EBIT Margin (2023 - 2025)

Historic EBIT Margin for Immunome (IMNM) over the last 3 years, with Q2 2025 value amounting to 1157.61%.

  • Immunome's EBIT Margin rose 5348200.0% to 1157.61% in Q2 2025 from the same period last year, while for Sep 2025 it was 2419.9%, marking a year-over-year increase of 7145000.0%. This contributed to the annual value of 3382.37% for FY2024, which is 26010200.0% down from last year.
  • According to the latest figures from Q2 2025, Immunome's EBIT Margin is 1157.61%, which was up 5348200.0% from 1525.5% recorded in Q1 2025.
  • In the past 5 years, Immunome's EBIT Margin registered a high of 129.96% during Q3 2023, and its lowest value of 12857.05% during Q1 2024.
  • Its 3-year average for EBIT Margin is 2492.75%, with a median of 1608.96% in 2025.
  • Its EBIT Margin has fluctuated over the past 5 years, first tumbled by -126679200bps in 2024, then skyrocketed by 113315500bps in 2025.
  • Immunome's EBIT Margin (Quarter) stood at 2473.94% in 2023, then decreased by -22bps to 3030.31% in 2024, then skyrocketed by 62bps to 1157.61% in 2025.
  • Its EBIT Margin was 1157.61% in Q2 2025, compared to 1525.5% in Q1 2025 and 3030.31% in Q4 2024.